[The chick embryo chorioallantioc membrane as a model for in vivo research on anti-angiogenesis in endometriosis].
OBJECTIVE
To establish the chick embryo chorioallantioc membrane (CAM) as a model for in vivo research on endometriosis. The model was used to investigate the mechanism of anti-vascular endothelial growth factor (VEGF) antibody for treatment of endometriosis.


METHODS
Human endometrial fragments were explanted onto the CAM. Then anti-VEGF antibody was used for the endometriosis-like lesions after transplantation of human endometrial fragments. The CAM models were treated respectively as control groups and experimental groups. The terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL), proliferating cell nuclear antigen (PCNA) and microvessel density (MVD) were used in vivo for analysis of anti-angiogenesis.


RESULTS
The apoptosis intensity of anti-VEGF antibody treated groups (6.7 +/- 0.9, 6.9 +/- 0.8) was significantly higher than that of the control groups (5.0 +/- 0.9, 5.4 +/- 1.1; P < 0.05). The proliferation intensity was not different in these groups. Lower MVD was observed in experimental groups [(4.2 +/- 1.1), (4.9 +/- 1.2) vessels] than the control groups [(6.9 +/- 1.6), (9.1 +/- 3.0) vessels; P < 0.05].


CONCLUSIONS
CAM is an extraembryonic membrane that is commonly used in vivo for the study of angiogenesis and anti-angiogenesis. Anti-VEGF antibody can be used to accelerate apoptosis of the endometrial cells and vascular endothelium cells, but it has no effect on the proliferation of these cells.
Wang
Han-bi
HB
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Leng
Jin-hua
JH
Zhu
Lan
L
Liu
Zhu-feng
ZF
Sun
Da-wei
DW
Lang
Jing-he
JH
D000482:Allantois; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002642:Chick Embryo; D004715:Endometriosis / Q000473:pathology / Q000628:therapy*; D004727:Endothelium / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009389:Neovascularization, Pathologic; D042442:Vascular Endothelial Growth Factors / Q000276:immunology*
D000906:Antibodies; D042442:Vascular Endothelial Growth Factors